基于血管质量倡议的透析终末期肾病患者CLTI血运重建后3年死亡风险评分
本研究利用美国血管质量倡议数据库纳入38,144例因慢性肢体威胁性缺血(CLTI)接受开放或腔内血运重建的终末期肾病(ESRD)透析患者,三分之二用于建立风险评分、三分之一用于验证。多变量Cox回归筛选与3年死亡相关的变量并赋分,评分≤0时死亡率25%,评分≥17时3年死亡率超过90%。术后使用他汀、抗血小板药和ACE抑制剂与生存改善显著相关。
要点
- 该评分可预测ESRD透析CLTI患者血运重建后3年死亡风险。
- 评分≤0时3年死亡率25%,评分≥17时超过90%。
- 术后使用他汀、抗血小板药和ACE抑制剂与生存改善独立相关。
核心结论
- 建立并验证了ESRD透析CLTI患者血运重建后3年死亡风险评分,术后他汀、抗血小板药和ACE抑制剂使用是改善生存的关键可干预因素。
研究设计与样本
- 基于美国血管质量倡议数据库的回顾性队列研究,纳入38,144例因CLTI接受开放或腔内血运重建的ESRD透析患者。
- 三分之二患者为风险评分创建队列,三分之一为验证队列,采用时间依赖多变量Cox回归筛选变量并按回归β系数赋分。
主要发现
- 多变量分析中与主要结局显著相关的变量包括:年龄每增10岁(>50岁后各十年P<.001)、BMI<20 kg/m2(HR 1.32)、BMI>35 kg/m2(保护性,HR 0.873)、CAD病史(HR 1.09)、5年前CAD血运重建(HR 1.12)、5年内CAD血运重建(HR 1.12)、CHF I级(HR 1.20)、II级(HR 1.25)、III级(HR 1.41)、IV级(HR 1.86)、COPD无药物(HR 1.10)、COPD用药(HR 1.18)、COPD用氧(HR 1.406)、养老院状态(HR 1.11)、既往颈动脉内膜剥脱或支架(HR 1.18)、术后未用抗血小板(HR 1.67)、未用他汀(HR 2.12)、未用ACE抑制剂(HR 1.26)。
- 保护性变量包括:术前未用他汀(HR 0.611)、出院双联抗血小板(HR 0.910)、BMI>35 kg/m2(HR 0.873)。
- 评分≤0时3年死亡率为25%,评分≥17时3年死亡率超过90%,事件率随评分增加而显著升高(OR有统计学意义)。
- 术后使用他汀和ACE抑制剂/ARB的获益显著(P<.001),与术前他汀状态或基线高血压无关。
关键数值与推荐
- 风险评分≤0对应3年死亡率25%,评分≥17对应3年死亡率超过90%。
临床怎么用
- 可用于ESRD透析CLTI患者血运重建前的风险分层,辅助医患决策。
- 术后应重视他汀、抗血小板药和ACE抑制剂的使用以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to create a validated risk score for the outcome of mortality within 3 years of revascularization for chronic limb-threatening ischemia (CLTI) in end-stage renal disease (ESRD) patients on dialysis. METHODS: Querying the United States-based data in the Vascular Quality Initiative identified 38,144 patients with ESRD undergoing open surgical or endovascular revascularization for CLTI. Two-thirds and one-third of the patients were divided into a risk score creation testing cohort and a validation cohort, respectively. Time-dependent multivariable Cox regression was performed utilizing variables associated with the outcome in the univariable analysis (P < .05). Variables with a P value of ≤.05 in the multivariable regression were included in the risk score and weighted based on their respective regression beta-coefficients on a point scale. Variables with a beta-coefficient of <.2 were assigned 1 point; then, a point was added for each increase in beta-coefficient at .2 intervals. A total score was then established for each patient based on the individual prevalence of the significant covariates. The mean 3-year mortality rate at each risk score bundle was calculated. The risk score was then applied to the validation cohort, who were not utilized for risk score creation, and event rates were compared between the testing and validation cohorts. RESULTS: Multivariable significance toward the primary outcome was noted in the testing cohort for (P < .01 for all): suprainguinal bypass procedure (hazard ratio [HR] reference); suprainguinal bypass in combination with infrainguinal artery bypass (HR, 1.86); body mass index (BMI) < 20 kg/m2 (HR, 1.32); BMI > 35 kg/m2 (protective) (HR, 0.873); advancing age with each decade over the age of 50 years (P < .001 at each decade); history (Hx) of coronary artery disease (CAD; HR, 1.09); Hx of CAD revascularization over 5 years ago (HR, 1.12); CAD revascularization less than 5 years ago (HR, 1.12); congestive heart failure (CHF) class I (HR, 1.20); CHF class II (HR, 1.25); CHF class III (HR, 1.41); CHF class IV (HR, 1.86); no medicines in chronic obstructive pulmonary disease (COPD) (HR, 1.10); medicine use in COPD (HR, 1.18); oxygen use in COPD (HR, 1.406); nursing home status (HR, 1.11); prior carotid endarterectomy or stenting (HR, 1.18); absence of preoperative statin (protective HR, 0.611); dual antiplatelet at post-procedure discharge (protective HR, 0.910); absence of post-procedure antiplatelet (HR, 1.67), statin (HR, 2.12), and angiotensin-converting enzyme inhibitor (HR, 1.26); Asian race (HR, 1.25); White race (HR, 1.28); and unidentified race (HR, 1.12). Race HR was calculated with reference to the Black race HR. The mortality rate markedly increased, with event rates of 25% at the risk scores of ≤0 that increased to a 3-year mortality rate over 90% at the total risk score of 17 and higher. The odds ratio of the event rate was statistically significant with each increase in the risk score bundle. Subanalysis of baseline statin and hypertension revealed the significant (P < .001) benefits of statin therapy and angiotensin-converting enzyme/angiotensin receptor blocker at post-revascularization discharge, regardless of preoperative statin status or baseline hypertension. CONCLUSIONS: A novel validated risk score for mortality within 3 years of revascularization for CLTI in patients with ESRD has been created. Key modifiable variables that significantly enhance survival are the postoperative utilization of statin, antiplatelet, and ACE inhibitor medications (irrespective of baseline hypertension).
引用
- Rodriguez PP, Hallare J, Thakur P, et al. Vascular Quality Initiative-based risk score for mortality within 3 years of revascularization for chronic limb-threatening ischemia in end-stage renal disease patients on dialysis. J Vasc Surg. 2026. PMID: 42744008. doi:10.1016/j.jvs.2026.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。